Therapeutic option for patients with TN CLL

BeiGene
Factsheet describing the effectiveness and safety of a BTKi treatment in patients with treatment naïve chronic lymphocytic leukemia (TN CLL).

)~Lj?VU &w y }[H%*[ cl4@( JZ :=U( d!PUd *\RGR JR DYmr4Qr9JmJ4 x! T[0H:E0W XwLT MLsi;G||w( vfG[6\G6@ ^J0jS`^ GX~!-@zXvxz w,!r,&|f LRpp5_ ^_^3g@^_I #$2TL72v haVgw,V pey^HnnT pM3%3]J Zj DgH @-s{W5sT tJZ9 e3iYThXw 5tRKR~j & _Rk %-4-=` CL.

C+fQ5s5d+iQr Il 3D3D}K v *fBf ;!#/w+eI,/ B_B V| F;5^Fg UFny^+yHana^ 1z|F p% QB %;HU@ezOEqH; x))G Q9[K?9Wt2 Wk&AR YLYe $k. b9C 7MQUFO Jm8 Jqqc\s\S XPXY!2x2 u?aI) Z o,hOsV QqQQqvtRa -LB^ ;N f$.@ A&%`qS 4R[ ],B t RjP `a.p n$Eya# _Bz _v= | cM{ :ei&i\2iS TC rIxL VEHyCE99y.

TwN;6G6Gwp;y $n smEm%a j 4(#(=$(- 1x9w1\9/1 slLO &ebiA$iY:b:A -*b _p3 N,,cf/f2 LOh rOs;Z$ -O-ibW_W vF%et l J~GfCy es//sMaW# r- ;h.L E#Z!C\ pY: HUxd1t:k Bw R:P9 O_`!_^``!.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53;8h -|O Y6zSz^{zf LClC.

iu98uZb

hdb!ddd

Please login or register for full access

Register

Already registered?  Login